Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
1. New board members bring extensive corporate and commercialization experience. 2. Cytisinicline's NDA submission is expected in Q2 2025. 3. Cytisinicline targets a significant market with high nicotine dependence globally. 4. Expertise of new board members may enhance commercialization strategies. 5. Company focuses on smoking cessation amid increasing nicotine addiction rates.